BUSINESS

Takeda Files Teva’s Parkinson’s Disease Med in Japan

June 30, 2017

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Takeda Pharmaceutical said on June 29 that it has filed a new drug application in Japan for the Parkinson’s disease treatment rasagiline mesylate, which will be the company’s first Parkinson’s disease drug if approved. Developed by Teva Pharmaceutical Industries, rasagiline…

To read the full story

Teva’s Parkinson’s Med Delivers Positive Data in Japan PIII: Takeda
September 22, 2017

BUSINESS

Takeda Hands CEO Baton to Kim after 12-Year Weber Era
June 25, 2026
Tanabe Starts Long-Term Uplizna Study in IgG4-Related Disease
June 25, 2026
ASKA Shareholders Back Faster Poison Pill Activation
June 25, 2026
EU Approves Padcev-Keytruda for Earlier Bladder Cancer Use
June 25, 2026
Tacrolimus Generics Add Cell Transplantation Indication
June 25, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry

By Philip Carrigan

Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…